Schedule 13G ownership disclosure

ArriVent Biopharma Inc

Common Stock · CUSIP: 04272N102

Event date: 2025-05-01

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • INFINITUM ASSET MANAGEMENT, LLC

    Shares: 3,418,923.00 · Class: 9.9%

  • Infinitum Cayman Master, Ltd. (Fund)

    Shares: 3,418,923.00 · Class: 9.9%

  • Infinitum Partners GP, LLC

    Shares: 3,418,923.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002058093-25-000008
Form type
SCHEDULE 13G
Filer
ArriVent BioPharma, Inc.
CIK
CIK 1868279
Filed
Aug 13, 2025
Reporting period
May 01, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub